

PKI 14-22 amide, myristoylated Acetate

Chemical Properties

CAS No. :


Formula: C55H104N20O14

Molecular Weight: 1269.54

Keep away from moisture

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	PKI 14-22 amide, myristoylated Acetate inhibit cAMP-dependent protein kinase (PKA) and blocks hyperalgesia produced by spinal administration of 8-bromo-cAMP.
Targets(IC50)	PKA
In vitro	?Myristoylated PKI 14-22 amide reduced the IgG-mediated phagocytic response in a manner of dose-dependent.?When the concentration is higher than 10 μ M, PKI 14-22 amide can inhibit neutrophil adhesion, which make the phagocytosis measurements impossible to perform

Solubility Information

Solubility	DMSO: 55 mg/mL (43.32 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.7877 mL	3.9384 mL	7.8769 mL
5 mM	0.1575 mL	0.7877 mL	1.5754 mL
10 mM	0.0788 mL	0.3938 mL	0.7877 mL
50 mM	0.0158 mL	0.0788 mL	0.1575 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

drenius L1, Majeed M, etal. , Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosis. J Leukoc Biol. 2000 Apr;67(4):520-8.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481